The borderline condition between normal aging and dementia should be detected to predict further deterioration. The authors cross-sectionally analyzed neuropsychological data, memory complaints, and social activities for communitydwelling older adults. The rate of decline from Clinical Dementia Rating (CDR) 0.5 to dementia during a 3-year interval was also analyzed. Short-term memory rather than long-term memory was found to be sensitive in distinguishing those with CDR 0 from those with CDR 0.5. Relatives’ observations of memory decline rather than subjective memory complaints were significantly different. Participants with CDR 0.5 reported fewer problems with social activities than did their relatives. Ten of the 29 CDR 0.5 participants (34.5%) showed cognitive decline, the decliners showing lower scores on short-term memory and orientation at the baseline condition. The neuropsychological data showed CDR 0.5 to be similar to very mild Alzheimer’s disease. It would be better if subjective complaints were excluded from the criteria of the borderline condition.
1. Ishizaki J, Meguro K, Ohe K, et al. Therapeutic psychosocial intervention for elderly subjects with very mild AD in a community: the Tajiri project. Alzheimer Dis Assoc Disord. 2002; 16:261-269.
2.
2. Petersen RC, Smith GE, Waring SC, et al. Aging, memory and mild cognitive impairment. Int Psychogeriatr. 1997; 9:65-69.
3.
3. Carr DB, Gray B, Baty J, et al. The value of informant vs. individual’s complaints of memory impairment in early dementia. Neurology. 2000; 55:1724-1726.
4.
4. Hughes CP, Berg L, Danziger WL, et al. A new clinical scale for the staging of dementia. Br J Psychiatr. 1982; 140:566-572.
5.
5. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993; 43:2412-2414.
6.
6. Morris JC, McKeel DW Jr, Storandt M, et al. Very mild Alzheimer’s disease: informant-based clinical, psychometric, and pathologic distinction from normal aging. Neurology. 1991; 41:469-478.
7.
7. Morris JC, Storandt M, Miller JP, et al. Mild cognitive impairment represents early-stage Alzheimer’s disease. Arch Neurol. 2001; 58:397-405.
8.
8. What is MCI? Variations in definitions and evolution of nondemented persons with cognitive impairment. Acta Neurol Scand. 2003; 107(Suppl. 179):14-20.
9.
9. Palmer K, Wang HX, Backman L, et al. Differential evolution in nondemented older persons: results from the Kingsholmen Project. Am J Psychiatry. 2002; 159:436-442.
10.
10. Petersen RC, Smith GE, Waring SC, et al. MCI: clinical characterization and outcome. Arch Neurol. 1999; 56:303-308.
11.
11. Schofield P, Marder K, Dooneief G, et al. Association of subjective memory complaints with subsequent cognitive decline in community-dwelling elderly individuals with baseline cognitive impairment. Am J Psychiatry. 1997; 154:609-615.
12.
12. Johansson B, Zarit SH. Early cognitive markers of the incidence of dementia and mortality: a longitudinal study of the oldest old. Int J Geriatr Psychiatry. 1997; 12:53-59.
13.
13. Flicker C, Ferris SH, Reisberg B.MCI in the elderly: predictors of dementia. Neurology. 1991; 41:1006-1009.
14.
14. Tierney MC, Szalai JP, Snow WG, et al. Prediction of probable AD in memory-impaired patients: a prospective longitudinal study. Neurology. 1996; 46:661-665.
15.
15. Crook T, Bartus RT, Ferris SH, et al. AAMI: proposed diagnostic criteria and measures of clinical change: report of a NIMH Work Group. Dev Neuropsychol. 1986; 2:261-276.
16.
16. Ritchie K, Artero S, Touchon J.Classification criteria for MCI. A population-based validation study. Neurology. 2001; 56:37-42.
17.
17. Braekhus A, Laake K, Engedal K.A low “normal” score on the MMSE predicts development after three years. J Am Geriatr Soc. 1995; 43:656-661.
18.
18. Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975; 12:189-198.
19.
19. Ambo H, Meguro K, Ishizaki J, et al. Depressive symptoms and associated factors in a cognitively normal elderly population: the Tajiri Project. Int J Geriatr Psychiatry. 2001; 16:780-788.
20.
20. Ishizaki J, Meguro K, Ambo H, et al. A normative, communitybased study of MMS in elderly adults: the effect of age and educational level. J Gerontol Psychol Sci. 1998; 53B:359-363.
21.
21. Ishii H, Meguro K, Ishizaki J, et al. Prevalence of senile dementia in a rural community in Japan: the Tajiri Project. Arch Gerontol Geriatr. 1999; 29:249-265.
22.
22. Meguro K, Ishii H, Yamaguchi S, et al. Prevalence of dementia and dementing diseases in Japan: the Tajiri Project. Arch Neurol. 2002; 59:1109-1114.
23.
23. Teng EL, Hasegawa K, Homma A, et al. The CASI: a practical test for cross-cultural epidemiological studies of dementia. Int Psychogeriatr. 1994; 6:45-58.
24.
24. McKeith LG, Galasjo D, Kosaka K, et al. Consensus guidelines for the clinical and pathologic diagnosis of DLB: report of the Consortium on DLB International Workshop. Neurology. 1996; 47:1113-1124.
25.
25. The Lund and Manchester Groups. Clinical and neuropathological criteria for frontotemporal dementia. J Neurol Neurosurg Psychiatry. 1994; 57:416-418.
26.
26. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of AD: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services task force on AD. Neurology. 1984; 34:939-944.
27.
27. Otoyama W, Niina R, Homma A, et al. Inter-rater reliability of the Japanese version of CDR. Jpn J Geriatr Psychiatry. 2000; 11:521-527.
28.
28. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed.Washington, DC: American Psychiatric Association, 1994.
29.
29. Meguro K, Ishii H, Yamaguchi S, et al. Prevalence and cognitive performances of Clinical Dementia Rating 0.5 and mild cognitive impairment in Japan: The Tajiri Project. Alz Dis Ass Dis. 2004; 18:3-10.
31. Schroder J, Kratz B, Pantel J, et al. Prevalence of MCI in an elderly community sample. J Neural Transm. 1998; 54(Suppl):51-59.
32.
32. Busse A, Bischkopf J, Riedel-Heller SG, et al. Mild cognitive impairment: prevalence and incidence according to different diagnostic criteria. Br J Psychiatry. 2003; 182:449-454.
33.
33. Dely E, Zaitchik D, Copeland M, et al. Predicting conversion to Alzheimer’s disease using standardized clinical information. Arch Neurol. 2000; 57:643-644.
34.
34. The Canadian Study of Health and Aging Working Group. The incidence of dementia in Canada. Neurology. 2000; 55:66-73.
35.
35. Fratiglioni L, Viitanen M, von Strauss E, et al. Very old women at higher risk of dementia and Alzheimer’s disease: incidence data from the Kungsholmen Project, Stockholm. Neurology. 1997; 48:132-138.
36.
36. Devanand DP, Folz M, Gorlyn M, et al. Questionable dementia: clinical course and predictors of outcome. J Am Geriatr Soc. 1997; 45:321-328.
37.
37. Petersen RC, Smith GE, Ivnik RJ, et al. Apolipoprotein Estatus as a predictor of the development of AD in memory-impaired individuals. JAMA. 1995; 273:1274-1278.
38.
38. Small GW, La Rue A, Komo S, et al. Predictors of cognitive change in middle-aged and older adults with memory loss. Am J Psychiatry. 1995; 50:380-383.
